Merck tops third-quarter estimates as Keytruda, Gardasil outperform

Merck reported Q3 revenue of $18.1B, beating estimates of $17.3B. Keytruda sales rose 6% to $8.6B, and Gardasil sales increased 14% to nearly $2B. Merck raised its full-year revenue forecast to $66.8B-$67.3B and adjusted earnings outlook to $2.77-$2.82 per share. The company has been diversifying its portfolio, with Winrevair sales up 94% to $694M. Merck shares are up 34% this year.

Original reporting
Published Oct 29, 2026, 10:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 10:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Merck tops third-quarter estimates as Keytruda, Gardasil outperform — source image
Decision brief

The 30-second read

$MRKBullishHigh
01

Why it matters

Earnings beat and guidance raise suggest continued revenue momentum, but future patent cliffs remain a risk.

02

Market read

Merck's earnings beat and raised outlook are likely to lift the stock and positively influence the broader healthcare sector.

03

What to watch

Potential competitive pressure from biosimilars could temper long-term growth.

Relevance 9/10Novelty 9/10Timing: post-market today

Background

Merck's Q3 results highlight strong performance of Keytruda and Gardasil, with early purchases boosting sales.

Company-level read

Ticker impact

$MRKBullishHigh confidence
Context

Merck reported Q3 earnings beating estimates and raised full-year revenue and earnings guidance.

Expected impact

upward pressure as investors price in stronger revenue and earnings outlook

Evidence & confidence

Beat on revenue and EPS, plus raised guidance, typically drive buying interest.

Market effects

Boosts biotech/pharma sector sentiment, especially peers with immunotherapy pipelines.

Supports US large-cap health care index performance.

Reinforces confidence in US pharma earnings outlook globally.

Counterpoint

Some investors may worry about upcoming patent expirations for Keytruda starting 2028.

Key entities

  • Merck

    US pharmaceutical giant reporting Q3 results.

Related articles

$MRKHigh

Why Merck (MRK) Stock Is Down Today

Merck (MRK) shares fell 3.8% after the company discontinued the BELLWAVE clinical program for nemtabrutinib, citing potential risks outweighing benefits in a Phase 3 trial. The decision impacts multiple studies, marking a pipeline setback for the drugmaker. Merck's latest earnings report had shown revenue growth and pipeline activity before this development.

$MRKHigh

Merck wins all 14 U.S. patent reviews against Halozyme

Merck (MSD) won all 14 U.S. patent reviews against Halozyme, securing its Keytruda Qlex cancer immunotherapy's subcutaneous injection technology. The Patent Trial and Appeal Board ruled all challenged claims unpatentable. Keytruda Qlex sales reached $830M in Q3, 9.7% of total Keytruda sales. Halozyme may appeal, and a patent infringement lawsuit is ongoing.